Aspire BioPharma, Inc. (ASBP) — Cash Flow-to-Debt Ratio
Aspire BioPharma, Inc. (ASBP) has a Cash Flow-to-Debt Ratio of -0.94x as of March 2026, meaning its operating cash flow of $-3.04 Million could theoretically repay -1% of its total liabilities ($3.25 Million) in one year. See Aspire BioPharma, Inc. free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Aspire BioPharma, Inc. Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for Aspire BioPharma, Inc. across 5 annual periods. For the full cash flow conversion analysis, see ASBP cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Aspire BioPharma, Inc. (2021–2025)
Year-by-year debt coverage analysis for Aspire BioPharma, Inc.. Check Aspire BioPharma, Inc. earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.64x | $-4.92 Million | $7.69 Million | ▼ -307.6% |
| 2024 | -0.16x | $-265.19K | $1.69 Million | ▲ +90.3% |
| 2023 | -1.62x | $-653.11K | $403.33K | ▼ -1177.7% |
| 2022 | -0.13x | $-1.41 Million | $11.12 Million | ▼ -14216.2% |
| 2021 | 0.00x | $-260.00 | $293.70K | — |